Zobrazeno 1 - 10 of 40 pro vyhledávání: '"Gloria Patrick"'
1
Abstract CT204: A phase 1/2 study of VS-6766 in combination with sotorasib in patients with KRAS G12C mutant non-small cell lung cancer (NSCLC) (RAMP 203)
Autor: Ramaswamy Govindan, Jonathan A. Pachter, Andrew G. Koustenis, Gloria Patrick, Louis J. Denis
Publikováno v: Cancer Research. 82:CT204-CT204
Background: KRAS is mutated (mt) in 25% of non-small cell lung cancer (NSCLC) adenocarcinoma, with KRAS G12C mt occurring in ~13% of patients. The G12C inhibitor (G12Ci) sotorasib has recently received FDA approval for patients with KRAS G12C mt NSCL
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9c9dcdb1dc395f03a45aa6506e196e7
https://doi.org/10.1158/1538-7445.am2022-ct204
Zobrazit plný text záznamu
2
A phase 1/2 study of VS-6766 (RAF/MEK clamp) in combination with sotorasib (G12C inhibitor) in patients with KRAS G12C mutant non–small cell lung cancer (NSCLC) (RAMP 203)
Autor: Ramaswamy Govindan, Mark M. Awad, Shirish M. Gadgeel, Jonathan A. Pachter, Gloria Patrick, Louis J. Denis
Publikováno v: Journal of Clinical Oncology. 40:TPS9148-TPS9148
TPS9148 Background: KRAS is mutated (mt) in 25% of non-small cell lung cancer (NSCLC) adenocarcinoma, with KRAS G12C mt occurring in ̃13% of patients. The G12C inhibitor (G12Ci) sotorasib has recently received FDA approval for patients with KRAS G12
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::67e85ff2c4edb641c9d9ffa09a994491
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9148
Zobrazit plný text záznamu
3
A phase 2 study of VS-6766 (RAF/MEK clamp) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS mutant (mt) and BRAF mt non–small cell lung cancer (NSCLC)
Autor: D. Ross Camidge, Joshua E. Reuss, Alexander I. Spira, Pasi A. Janne, Muneeb Rehman, Jonathan A. Pachter, Gloria Patrick, Louis J. Denis, David R. Spigel
Publikováno v: Journal of Clinical Oncology. 40:TPS9147-TPS9147
TPS9147 Background: KRAS is mutated (mt) in 25% of NSCLC adenocarcinoma, with KRAS G12V and G12C mt occurring in ̃7% and ̃13% of patients (pts), respectively. Whereas G12C inhibitors have demonstrated promising activity in pts with KRAS G12C NSCLC,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3b6dc493b836426aab7245c7139008c3
https://doi.org/10.1200/jco.2022.40.16_suppl.tps9147
Zobrazit plný text záznamu
5
Abstract P048: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) RAMP 202, as a single agent and in combination with defactinib (FAK inhibitor) in recurrent KRAS-mutant (KRAS-MT) non-small cell lung cancer (NSCLC)
Autor: D. Ross Camidge, Jonathan Pachter, Andrew Koustenis, Gloria Patrick, David R. Spigel
Publikováno v: Molecular Cancer Therapeutics. 20:P048-P048
Background: VS-6766 is a unique small molecule inhibitor of both RAF and MEK. In contrast to several other MEK inhibitors available, VS-6766 blocks both MEK kinase activity and RAF phosphorylation of MEK. This sequential blockade mechanism enables VS
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::23c85c30e34f8ad3bb5ee332ffa35291
https://doi.org/10.1158/1535-7163.targ-21-p048
Zobrazit plný text záznamu
8
A Phase 2, Randomized, Open-Label, 2-Arm Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) (TEMPO)
Autor: Stephanie Lustgarten, Alena Zalutskaya, Leo I. Gordon, Narayana I. Narasimhan, Hagop Youssoufian, Reem Karmali, K. M. Sprott, Gloria Patrick, David T. Weaver
Publikováno v: Blood. 134:5251-5251
Background Duvelisib, an oral dual PI3K-δ and PI3K-γ inhibitor, is approved by the US Food and Drug Administration for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior systemic therapies.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c3c52b3452ed397283ce4f0c1e48c15e
https://doi.org/10.1182/blood-2019-124406
Zobrazit plný text záznamu
10
Inadequacies of Self-Report Data for Exclusion Criteria Detection in Marihuana Research
Autor: Frederick A. Struve, John J. Straumanis, Mary-Jo Fitzgerald, John Leavitt, Gloria Patrick, Joseph E. Manno
Publikováno v: Journal of Addictive Diseases. 19:71-87
Stringent exclusion criteria in drug abuse research are necessary to protect against methodological confounds compromising the interpretation of findings. However, reliance on self-report screening may fail to detect important exclusion variables. We
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::960e685dfd639a5e2d840d1a5fe61d53
https://doi.org/10.1300/j069v19n03_06
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje